Bicara Therapeutics Inc. financial data

Symbol
BCAX on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2276% %
Debt-to-equity 4.3% %
Return On Equity -27% % 97%
Return On Assets -26% %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 54,781,950 shares 0.67%
Common Stock, Shares, Outstanding 54,612,477 shares 0.37%
Entity Public Float $0 USD
Common Stock, Value, Issued $7,000 USD 0%
Weighted Average Number of Shares Outstanding, Basic 54,563,864 shares 401%
Weighted Average Number of Shares Outstanding, Diluted 54,563,864 shares 401%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $112,000,000 USD 108%
General and Administrative Expense $29,131,000 USD 62%
Operating Income (Loss) $141,119,000 USD -97%
Nonoperating Income (Expense) $19,948,000 USD 39%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $121,171,000 USD -108%
Income Tax Expense (Benefit) $343,000 USD
Net Income (Loss) Attributable to Parent $121,521,000 USD -104%
Earnings Per Share, Basic 33 USD/shares 58%
Earnings Per Share, Diluted 33 USD/shares 58%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $171,673,000 USD -67%
Assets, Current $297,372,000 USD -43%
Property, Plant and Equipment, Net $135,000 USD 3.8%
Operating Lease, Right-of-Use Asset $1,969,000 USD 376%
Other Assets, Noncurrent $7,795,000 USD 269%
Assets $424,688,000 USD -19%
Employee-related Liabilities, Current $3,990,000 USD 121%
Accrued Liabilities, Current $12,875,000 USD 60%
Liabilities, Current $21,028,000 USD 45%
Operating Lease, Liability, Noncurrent $880,000 USD 542%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $21,908,000 USD 50%
Accumulated Other Comprehensive Income (Loss), Net of Tax $136,000 USD
Retained Earnings (Accumulated Deficit) $321,580,000 USD -61%
Stockholders' Equity Attributable to Parent $402,780,000 USD -21%
Liabilities and Equity $424,688,000 USD -19%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $28,106,000 USD -93%
Net Cash Provided by (Used in) Financing Activities $460,000 USD 236%
Net Cash Provided by (Used in) Investing Activities $0 USD -100%
Common Stock, Shares Authorized 500,000,000 shares 0%
Common Stock, Shares, Issued 54,612,477 shares 0.34%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $27,646,000 USD -92%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $171,673,000 USD -67%
Deferred Tax Assets, Valuation Allowance $59,017,000 USD 57%
Deferred Tax Assets, Gross $59,199,000 USD 56%
Operating Lease, Liability $738,000 USD
Depreciation $19,000 USD 46%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $36,466,000 USD -109%
Lessee, Operating Lease, Liability, to be Paid $771,000 USD
Operating Lease, Liability, Current $1,095,000 USD 256%
Lessee, Operating Lease, Liability, to be Paid, Year Two $132,000 USD
Lessee, Operating Lease, Liability, to be Paid, Year One $639,000 USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $33,000 USD
Deferred Tax Assets, Operating Loss Carryforwards $25,269,000 USD 17%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Additional Paid in Capital $724,489,000 USD 2.1%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense $13,738,000 USD 78%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%